An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
← catalyst calendarNCT03950232 · readout in 1,035 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With Arena is a wholly owned subsidiary of Pfizer.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
896actual
Sites
470
Countries
Argentina, Australia, Austria +36
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-09-05 | actual | When the study began enrolling |
| Primary completion | 2029-06-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-19 | estimated | The whole study's end, after follow-up |
| First posted | 2019-05-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Intervention
- Drug: Etrasimod — also filed as APD334
Primary outcome
what the primary-completion date above is the date OFNumber and Severity of Safety Measures
measured Up to approximately 8 years
Publications
- PMID 39778975 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed